Opinion/decision on a Paediatric investigation plan (PIP): Nuvaxovid, Severe acute respiratory syndrome coronavirus 2 recombinant spike protein nanoparticle vaccine/ matrix-M1 adjuvant (NVX-CoV2373), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Vaccines, PIP number: P/0423/2023

Opinion/decision on a Paediatric investigation plan (PIP): Plegridy, peginterferon beta-1a, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0419/2023

Opinion/decision on a Paediatric investigation plan (PIP): Akynzeo, Fosnetupitant,Palonosetron, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0418/2023

Agenda of the PRAC meeting 25-28 November 2024

Human medicines European public assessment report (EPAR): Senshio, ospemifene, Date of authorisation: 14/01/2015, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Kauliv, teriparatide, Date of authorisation: 12/01/2023, Revision: 3, Status: Authorised

Stability testing for applications for variations to a marketing authorisation for veterinary medicinal products - Scientific guideline

Guideline on stability testing for applications for variations to a marketing authorisation for veterinary medicinal products

Overview of comments received on 'Guideline on stability testing for applications for variations to a marketing authorisation for veterinary medicinal products' (EMA/CVMP/QWP/515653/2023)

Committee for Herbal Medicinal Products (HMPC): 23-25 September 2024, European Medicines Agency, Amsterdam, the Netherlands, from 23 September 2024 to 25 September 2024